NASDAQ:IDXXIDEXX Laboratories Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IDEXX Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $374.03 -3.16 (-0.84 %) (As of 08/12/2020 04:00 PM ET) Add Compare Share Today's Range$372.18Now: $374.03▼$379.3950-Day Range$319.38MA: $353.98▼$397.7552-Week Range$168.65Now: $374.03▼$407.86Volume528,100 shsAverage Volume598,046 shsMarket Capitalization$31.81 billionP/E Ratio70.71Dividend YieldN/ABeta0.85 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.Read More Beat the Market (BTM) Rank™ 1.4 Analyst's Opinion Consensus RatingIDEXX Laboratories has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $353.40, IDEXX Laboratories has a potential downside of 5.5% from its current price of $374.03.Amount of Analyst CoverageIDEXX Laboratories has only been the subject of 3 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesIDEXX Laboratories has received 474 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIDEXX Laboratories has received 341 “underperform” votes. (Add your “underperform” vote.)Community SentimentIDEXX Laboratories has received 58.16% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote “Outperform” if you believe IDXX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIDEXX Laboratories does not currently pay a dividend.Dividend GrowthIDEXX Laboratories does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,539,817.00 in company stock.Percentage Held by InsidersOnly 2.53% of the stock of IDEXX Laboratories is held by insiders.Percentage Held by Institutions88.58% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IDEXX Laboratories are expected to grow by 12.37% in the coming year, from $5.66 to $6.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEXX Laboratories is 70.71, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 17.40.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEXX Laboratories is 70.71, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.03.Price to Earnings Growth RatioIDEXX Laboratories has a PEG Ratio of 4.40. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIDEXX Laboratories has a P/B Ratio of 180.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.19 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:IDXX Previous Symbol CUSIP45168D10 CIK874716 Webwww.idexx.com Phone207-556-0300Debt Debt-to-Equity Ratio3.54 Current Ratio1.44 Quick Ratio1.02Price-To-Earnings Trailing P/E Ratio70.71 Forward P/E Ratio66.08 P/E Growth4.4 Sales & Book Value Annual Sales$2.41 billion Price / Sales13.22 Cash Flow$5.89 per share Price / Cash Flow63.50 Book Value$2.07 per share Price / Book180.69Profitability EPS (Most Recent Fiscal Year)$4.89 Net Income$427.72 million Net Margins18.59% Return on Equity241.52% Return on Assets24.77%Miscellaneous Employees9,200 Outstanding Shares85,055,000Market Cap$31.81 billion Next Earnings Date10/29/2020 (Estimated) OptionableOptionable $374.03 -3.16 (-0.84 %) (As of 08/12/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive IDXX News and Ratings via Email Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter. IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions How has IDEXX Laboratories' stock price been impacted by Coronavirus? IDEXX Laboratories' stock was trading at $245.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IDXX stock has increased by 52.3% and is now trading at $374.03. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of IDEXX Laboratories? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IDEXX Laboratories. When is IDEXX Laboratories' next earnings date? IDEXX Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020. View our earnings forecast for IDEXX Laboratories. How were IDEXX Laboratories' earnings last quarter? IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its earnings results on Friday, July, 31st. The company reported $1.72 earnings per share for the quarter, beating analysts' consensus estimates of $1.17 by $0.55. The firm earned $637.20 million during the quarter, compared to the consensus estimate of $589.98 million. IDEXX Laboratories had a return on equity of 241.52% and a net margin of 18.59%. The business's revenue was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.43 earnings per share. View IDEXX Laboratories' earnings history. How will IDEXX Laboratories' stock buyback program work? IDEXX Laboratories announced that its board has initiated a stock repurchase program on Wednesday, February 12th 2020, which permits the company to repurchase 5,000,000 outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company's board of directors believes its stock is undervalued. What price target have analysts set for IDXX? 5 brokers have issued twelve-month price objectives for IDEXX Laboratories' stock. Their forecasts range from $277.00 to $415.00. On average, they anticipate IDEXX Laboratories' share price to reach $353.40 in the next twelve months. This suggests that the stock has a possible downside of 5.5%. View analysts' price targets for IDEXX Laboratories. Has IDEXX Laboratories been receiving favorable news coverage? Media stories about IDXX stock have been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IDEXX Laboratories earned a daily sentiment score of -4.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news about IDEXX Laboratories. Are investors shorting IDEXX Laboratories? IDEXX Laboratories saw a decrease in short interest during the month of July. As of July 31st, there was short interest totaling 1,590,000 shares, a decrease of 17.6% from the July 15th total of 1,930,000 shares. Based on an average daily volume of 511,600 shares, the short-interest ratio is currently 3.1 days. Approximately 1.9% of the company's shares are short sold. View IDEXX Laboratories' Short Interest. Who are some of IDEXX Laboratories' key competitors? Some companies that are related to IDEXX Laboratories include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Stryker (SYK), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and ABIOMED (ABMD). View all competitors. What other stocks do shareholders of IDEXX Laboratories own? Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), Paypal (PYPL), Mastercard (MA), Adobe (ADBE), Alibaba Group (BABA), Tesla (TSLA), Shopify (SHOP), Trade Desk (TTD) and Square (SQ). Who are IDEXX Laboratories' key executives? IDEXX Laboratories' management team includes the following people: Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 63)Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 57)Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Corp. Sec. (Age 60)Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 55)Mr. Jay Mazelsky, Exec. VP of Companion Animal Group (Age 58) What is IDEXX Laboratories' stock symbol? IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX." Who are IDEXX Laboratories' major shareholders? IDEXX Laboratories' stock is owned by many different institutional and retail investors. Top institutional investors include Blair William & Co. IL (1.82%), Principal Financial Group Inc. (1.46%), Bank of New York Mellon Corp (0.83%), Goldman Sachs Group Inc. (0.63%), Sumitomo Mitsui Trust Holdings Inc. (0.42%) and Swiss National Bank (0.40%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Giovani Twigge, Jacqueline Studer, James F Polewaczyk, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek. View institutional ownership trends for IDEXX Laboratories. Which institutional investors are selling IDEXX Laboratories stock? IDXX stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Sumitomo Mitsui Trust Holdings Inc., EULAV Asset Management, Robeco Institutional Asset Management B.V., Ardevora Asset Management LLP, Barclays PLC, William Blair Investment Management LLC, and Oregon Public Employees Retirement Fund. Company insiders that have sold IDEXX Laboratories company stock in the last year include Giovani Twigge, James F Polewaczyk, Jonathan W Ayers, M Anne Szostak, and Rebecca M Henderson. View insider buying and selling activity for IDEXX Laboratories. Which institutional investors are buying IDEXX Laboratories stock? IDXX stock was purchased by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Frontier Capital Management Co. LLC, Capital Investment Services of America Inc., Envestnet Asset Management Inc., Natixis Advisors L.P., Riverbridge Partners LLC, State of Wisconsin Investment Board, and Barometer Capital Management Inc.. View insider buying and selling activity for IDEXX Laboratories. How do I buy shares of IDEXX Laboratories? Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is IDEXX Laboratories' stock price today? One share of IDXX stock can currently be purchased for approximately $374.03. How big of a company is IDEXX Laboratories? IDEXX Laboratories has a market capitalization of $31.81 billion and generates $2.41 billion in revenue each year. The company earns $427.72 million in net income (profit) each year or $4.89 on an earnings per share basis. IDEXX Laboratories employs 9,200 workers across the globe. What is IDEXX Laboratories' official website? The official website for IDEXX Laboratories is www.idexx.com. How can I contact IDEXX Laboratories? IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected] This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
